Young-Donor Plasma

What the evidence says

Young-donor plasma is based partly on heterochronic-parabiosis experiments in which old and young animals share circulation. A plasma transfusion is not parabiosis, and neither animal model identifies a clinically validated rejuvenating product, dose, or schedule for humans.^[1][3]

The PLASMA study tested four weekly infusions from young donors in 18 people with mild-to-moderate Alzheimer disease. It primarily supported short-term feasibility; its size and design could not establish cognitive efficacy, and it does not support use in healthy people.^[2]

Small trials of GRF6019, a processed plasma-derived fraction, reported acceptable short-term tolerability and exploratory outcome patterns in Alzheimer disease. These products are not young-donor plasma, and uncontrolled or small randomized signals are insufficient for efficacy or general anti-aging claims.^[4][5]

Other research tests therapeutic plasma exchange or plasma dilution, which removes and replaces a patient's plasma rather than adding purported youth factors. A 2025 randomized trial may motivate larger studies, but it cannot be used as evidence that commercial young-plasma transfusions work.^[3][6]

The FDA states that young-donor plasma has no proven clinical benefit for aging, memory loss, dementia, or other marketed uses and warns of allergic reactions, transfusion-associated circulatory overload, acute lung injury, infection, and other harms. Paying for an unapproved infusion also risks delaying appropriate diagnosis and care.^[1]